{"@type":"dcat:Dataset","accessLevel":"public","bureauCode":["009:10"],"contactPoint":{"fn":"openFDA","hasEmail":"mailto:open@fda.hhs.gov"},"description":"<p>A 180-day supplement is a request for a significant change in components, materials, design, specification, software, color additive, and labeling to an approved premarket application or premarket report. As a pilot program under the CDRH Transparency Initiative, FDA has begun releasing some summary review memos for 180-day PMA supplements relating to design changes.</p>\n","identifier":"178c6833-1ea7-4215-b72b-bcdf26c48ed9","keyword":["cdrh"],"language":["en"],"license":"http://opendefinition.org/licenses/odc-odbl/","modified":"2016-09-02","programCode":["009:005"],"publisher":{"@type":"org:Organization","name":"Department of Health &amp; Human Services"},"title":"Premarket Approval (PMA) Summary Review Memos for 180-Day Design Changes"}
